3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Multiple Myeloma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fatigue
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Thrombocytopenia
1
Symptom Management
1
Stomach Neoplasms
1
Splenomegaly
1
Sexual Dysfunction, Physiological
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
liposomal doxorubicin
4
Temozolomide
4
Biopsy
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leiomyosarcoma
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled